Skip to main content

3 Result(s)

within Fumihiko Hirai Remove this filter Cancer Research Remove this filter Pharmacology/Toxicology Remove this filter

and

  1. Article

    Open Access

    Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours

    This was the first Phase I study to assess the safety and tolerability of the tablet formulation of olaparib (Lynparza™), an oral poly(ADP-ribose) polymerase inhibitor, in Japanese patients with advanced solid...

    Kan Yonemori, Kenji Tamura, Makoto Kodaira… in Cancer Chemotherapy and Pharmacology (2016)

    Download PDF (434 KB) View Article

  2. Article

    Open Access

    Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors

    Investigate the safety and tolerability of AZD5363 and define a recommended dose for evaluation in Japanese patients with advanced solid malignancies.

    Kenji Tamura, Jun Hashimoto, Yuko Tanabe… in Cancer Chemotherapy and Pharmacology (2016)

    Download PDF (496 KB) View Article

  3. No Access

    Article

    Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours

    AZD7762, a potent Chk1/Chk2 inhibitor, has shown chemosensitizing activity with gemcitabine in xenograft models.

    Takashi Seto, Taito Esaki, Fumihiko Hirai… in Cancer Chemotherapy and Pharmacology (2013)